Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 60.45% is 58% above its 5-year average of 38.23%, near the high end of its 5-year range (-552.34%–100.00%).
1.79% above its 12-month average of 59.39%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 50.65%.
GROSS MARGIN
60.45%
GROSS MARGIN AVG TTM
59.39%
GROSS MARGIN AVG 3Y
57.89%
GROSS MARGIN AVG 5Y
38.23%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.79%
CURRENT VS 3Y AVG
+4.42%
CURRENT VS 5Y AVG
+58.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+40.88%
vs the sector median at left
Market Cap
$2.06B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$2.05B
Gross Margin
86.13%
TTM Avg
85.03%
3Y Avg
84.60%
5Y Avg
84.81%
Market Cap
$2.11B
Gross Margin
32.36%
TTM Avg
32.47%
3Y Avg
32.14%
5Y Avg
31.56%
Market Cap
$2.02B
Gross Margin
90.36%
TTM Avg
88.22%
3Y Avg
91.04%
5Y Avg
93.63%
Market Cap
$2.01B
Gross Margin
17.11%
TTM Avg
17.72%
3Y Avg
20.44%
5Y Avg
20.08%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | 60.45% | 59.39% | 57.89% | 38.23% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | 97.82% | 97.53% | 97.80% | 96.20% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 86.13% | 85.03% | 84.60% | 84.81% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 32.36% | 32.47% | 32.14% | 31.56% |
| Immunome, Inc. (IMNM)vs › | $2.02B | 57.43% | 78.72% | 64.36% | 42.91% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 90.36% | 88.22% | 91.04% | 93.63% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 17.11% | 17.72% | 20.44% | 20.08% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 74.56% | 75.05% | 76.31% | 78.00% |
| Azenta, Inc. (AZTA)vs › | $1.97B | 44.05% | 44.96% | 41.63% | 40.93% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | 100.00% | -1064.88% | -1783.56% | -1442.31% |
Gross Margin
60.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 50.65% |
| 2026-03-31 | 56.47% |
| 2025-12-31 | 63.18% |
| 2025-09-30 | 69.26% |
| 2025-06-30 | 57.39% |
| 2025-03-31 | 50.70% |
| 2024-12-31 | 46.87% |
| 2024-09-30 | 61.31% |
| 2024-06-30 | 77.25% |
| 2024-03-31 | 45.85% |
| 2023-12-31 | -5.67% |
| 2023-08-31 | -105.34% |
| 2023-06-30 | -552.34% |
| 2023-03-31 | -146.44% |
| 2022-12-31 | -20.43% |
| 2022-09-30 | -18.91% |
| 2022-06-30 | 59.50% |
| 2022-03-31 | -286.73% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
